BridgeBio Pharma Stock News & Updates

[WKN: A2PLX7 | Symbol: BBIO]

BridgeBio Pharma

BridgeBio Pharma: Barclays sees 103% price potential after FDA approval of the drug Attruby

02/13/2026 at 12 PM

Deutsche Börse [DE0005810055] Barclays confirms Overweight rating and raises the price target from...

01/28/2026 at 01 PM

BridgeBio [US10806X1028] Barclays starts coverage with Overweight and a price target of $157 (100%...

10/30/2025 at 06 PM

Currently, our screening includes 23 biopharma stocks that have risen by at least 10% in the last 20...

09/01/2025 at 12 PM

Teamviewer [DE000A2YN900] Bank of America upgrades rating from Underperform to Buy and raises...

08/06/2025 at 10 AM

BridgeBio Pharma is a biotechnology company focused on the discovery, development, testing, and provision...

07/14/2025 at 11 AM

Harrow Inc. [US4158581094] Cantor Fitzgerald starts coverage with Overweight and a price target of...

04/15/2025 at 01 PM

Puma [DE0006969603]: Berenberg initiates coverage with a Buy rating and a price target of €40 (100%...

03/31/2025 at 04 PM

The biotech stock of BridgeBio Pharma (BBIO) has held up remarkably well in recent weeks. BridgeBio...

01/23/2025 at 03 PM

Genetic disorders are generally considered rare diseases, but when they do occur, they are usually associated...